How Has the Hepatic Encephalopathy Market Size Evolved in Recent Years?
The hepatic encephalopathy market has seen considerable growth due to a variety of factors.
• Significant growth has been observed in the hepatic encephalopathy market size in the past years. Anticipated to progress from $1.72 billion in 2024 to $1.8 billion in 2025, it is reviewed to achieve a compound annual growth rate (CAGR) of 5.1%.
The historic growth rate can be linked to factors such as the widespread occurrence of liver diseases, the escalating consciousness about hepatic encephalopathy, governmental efforts, and the rise in new liver therapies.
What are the Market Size and Expected Growth Rates for the Hepatic Encephalopathy Market?
The hepatic encephalopathy market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are high for significant expansion in the hepatic encephalopathy market over the upcoming years. The market is projected to reach a value of $2.23 billion by 2029, with a compound annual growth rate (CAGR) of 5.5%.
This forecasted surge can be attributed to factors such as an aging demographic, the introduction of new treatment avenues, an increase in spending on healthcare infrastructure, and investments in hepatic encephalopathy therapies. Other trends likely to play a pivotal role in this growth period include the unveiling of groundbreaking therapies, a rise in research and clinical trials, advancements in liver transplantation procedures, pharmaceutical innovation, progress in dietary management methods, as well as the adoption of telemedicine and remote monitoring practices.
Which Key Drivers Are Propelling The Hepatic Encephalopathy Market's Growth?
Anticipations abound for a surge in the hepatic encephalopathy market, mainly driven by the escalating incidence of liver diseases. Liver disease adversely affects liver function and conditions such as hepatic encephalopathy serve as an effective treatment plan. This helps to lessen the symptoms and slow the progress of the disease, thereby improving liver functionality, reducing the occurrence of hepatic encephalopathy, and improving patient quality of life by enhancing the management of underlying health conditions. This is corroborated by a report in April 2024 from the UK's Office for Health Improvement and Disparities, which showed an uptick in the hospital admission rates for liver disease from 150.6 (148.2 to 152.9) the preceding year to 155.2 per 100,000 population (with a range of 152.9 to 157.5) in the financial year closing 2023. Thus, this increasing trend in liver diseases is propelling the hepatic encephalopathy market growth. Further fueling the growth of the hepatic encephalopathy market is the rise in healthcare expenditures. Healthcare expenditures constitute the overall amount allocated towards healthcare services, goods, and activities usually at an individual, community, national or global level within a stipulated time frame. These expenses can favourably influence the hepatic encephalopathy treatment options, fostering progress in diagnosis, treatment, awareness, and patient care. This is evidenced by figures from the U.S. based Centers for Medicare & Medicaid Services, which state that in December 2023, health care spending in the U.S. blossomed by 4.1% in 2022, hitting $4.5 trillion which exhibits growth from the 3.2% increase the prior year. As such, it is emphatic that the rise in healthcare expenditure will stimulate the hepatic encephalopathy market growth.
What Are The Key Segments Within The Global Hepatic Encephalopathy Market?
The hepatic encephalopathy market covered in this report is segmented –
1) By Drug Class: Antibiotics, Laxatives, L-Ornithine, L-Aspartate, Other Drug Classes
2) By Route Of Administration: Oral, Intravenous, Rectal
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Antibiotics: Rifaximin, Neomycin, Metronidazole
2) By Laxatives: Lactulose, Polyethylene Glycol, Sorbitol
3) By L-Ornithine, L-Aspartate: L-Ornithine L-Aspartate
4) By Other Drug Classes: Zinc Supplements, Probiotics, Hepatoprotective Agents
Pre-Book The Hepatic Encephalopathy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Hepatic Encephalopathy Market?
Leading firms in the hepatic encephalopathy market are producing novel medications as part of their strategy to gain an edge over competitors and consolidate their position. For example, in June 2023, Karolinska Development AB, a pharmaceutical company from Sweden, introduced the experimental GR3027 (golexanolone) geared towards treating hepatic encephalopathy. This orally delivered small molecule is a GABAA-receptor-regulating steroid antagonist (GAMSA), engineered to oppose the positive modulation of GABAA-receptor by indigenous neuroactive steroids. Moreover, the pharmaceutical product is currently under examination for treating hepatic encephalopathy. The research trial is presently in Phases I/IIa for CHE.
Who Are the Key Players In The Hepatic Encephalopathy Market?
Major companies operating in the hepatic encephalopathy market are:
• Umecrine Cognition AB
• Bausch Health Companies Inc.
• Mallinckrodt Pharmaceuticals
• Lupin Limited
• Salix Pharmaceuticals
• Norgine B.V.
• Ferring B.V.
• ASKA Pharmaceutical Co. Ltd.
• Vedanta Biosciences Inc.
• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Bausch Health Companies Inc.
• Ochsner Health Inc.
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Amneal Pharmaceuticals LLC
• Mallinckrodt PLC
• Lupin Limited
• Torrent Pharmaceuticals Ltd.
• Salix Pharmaceuticals Inc.
• ASKA Pharmaceutical Co. Ltd.
• Norgine B.V.
What Are The Regional Insights Into The Hepatic Encephalopathy Market?
North America was the largest region in the hepatic encephalopathy market in 2024. The regions covered in hepatic encephalopathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
